Treating chronic migraines with behavioral approaches – such as biofeedback, relaxation training, and hypnosis – can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found. Longtime behavioral therapy researcher and practitioner Dr. Donald Penzien, University of Mississippi Medical Center professor of psychiatry, coauthored the study.
New research has suggested that tranexamic acid has the potential to prevent people dying from head injuries. The CRASH-2 Intracranial Bleeding Study highlights the potential of the cheap, off-patent drug to help people suffering from brain trauma, also known as traumatic brain injury (TBI). The results are now published online in the BMJ.
Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a “seeding trial” used by a pharmaceutical company to promote the drug and increase prescriptions, according to a report in the June issue of Archives of Internal Medicine, one of the JAMA/Archives journals. As described in […]
Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson’s disease (PD) in a mouse model of the condition. Preclinical research is now underway at the Buck Institute for Research on Aging to determine correct dosages for a drug that continues to be the gold standard for the treatment of bipolar […]
The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That is the finding of a study published in the June 23rd issue of the New England Journal of Medicine.
A study in mice has pinpointed a pivotal new player in triggering the rapid antidepressant response produced by ketamine. By deactivating a little-known enzyme, the drug takes the brakes off rapid synthesis of a key growth factor thought to lift depression, say NIMH-funded researchers.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications – quetiapine (Seroquel), a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer. The research is funded by a $10 million grant from the U.S. Agency for Healthcare Research Quality (AHRQ).
Headache is a very common complaint with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions. In a study published online today in the Journal […]
Recent Comments